Welcome to our dedicated page for Ironwood news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood stock.
Ironwood Pharmaceuticals, Inc. develops and commercializes therapies for gastrointestinal and rare diseases. Company news centers on LINZESS® (linaclotide), its commercial product for irritable bowel syndrome with constipation and chronic idiopathic constipation, including prescription demand, U.S. net sales, label-related regulatory updates, and pediatric functional constipation data.
Recurring updates also cover apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients dependent on parenteral support. Ironwood announcements frequently include quarterly results, financial guidance, cash flow and debt commentary, medical meeting presentations, and investor communications tied to its GI-focused research and commercialization strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will present pivotal Phase III data on linaclotide for treating functional constipation in children aged 6-17 at the 2023 Digestive Disease Week® (DDW) from May 6-9 in Chicago, IL. This condition affects around 6 million children in the U.S. An oral presentation will detail a clinical trial assessing the efficacy and safety of linaclotide 72 mcg in this age group. Four poster sessions will present further efficacy and safety data. Notably, the FDA granted Priority Review for a supplemental New Drug Application (sNDA) for linaclotide in pediatric use, with a PDUFA date set for June 14, 2023. Currently, there are no FDA-approved therapies for pediatric functional constipation. Ironwood continues to expand its research in this area.